Biotech partner would develop Enveric's three classes of compounds from its AI-powered drug discovery platform. Licensee to receive exclusive global licenses to develop and sublicense the three assets ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule ...
Potentially significant milestone payments and execution fees if all development and sales criteria are met for all three agreements. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback